Veracyte Acquires Convergent Genomics In $150M Deal, With Up To $30M Milestone Payments
Veracyte, Inc. (NASDAQ: VCYT ), a leading cancer diagnostics company, today announced its acquisition of Convergent Genomics. The acquisition adds Convergent Genomics’ UroAmp platform, including its proprietary urinary tumor DNA (utDNA) technology, to Veracyte’s product portfolio. To date, UroAmp has been clinically va